leadf
logo-loader
viewEmyria Ltd

Emerald Clinics announce new collaborations to enhance and expand its digital health platform

Emerald Clinics Ltd's (ASX:EMD) Dr Michael Winlo speaks to Proactive's Andrew Scott after announcing they've signed new agreements that he says will enhance its data capture technology platform and support the launch of a new digital health and clinical monitoring service called ‘Sentinel Plus’.

The company secured an agreement with artificial intelligence (AI) technology company, Binah.ai, to incorporate Binah’s world-leading smartphone technology into Emerald’s Real-World Evidence (RWE) engine as well as agreeing a deal with Linear Clinical Research to support the remote evaluation of more than 150 healthy volunteer trial participants over a two-year period for a Phase 1 COVID-19 vaccine study.

Quick facts: Emyria Ltd

Price: 0.077 AUD

ASX:EMD
Market: ASX
Market Cap: $16.28 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Emyria Ltd named herein, including the promotion by the Company of Emyria Ltd in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Zelira Therapeutics and Emyria team up for 'disruptive' autism spectrum...

Zelira Therapeutics Ltd's (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) Richard Hopkins and Emyria Ltd's (ASX:EMD) Michael Winlo speak to Proactive's Andrew Scott after announcing they've entered into an agreement to conduct an observational trial for patients diagnosed with autism spectrum disorder (ASD)...

2 weeks, 4 days ago

2 min read